Spedra (Avanafil)

Spedra (avanafil) is a PDE5-inhibitor for the treatment of erectile dysfunction, ED. It belongs to the second generation of a pharmaceutical group which brought major improvements for men suffering from ED when Viagra (sildenafil) was launched in 1998. Spedra was approved in the EU in 2014 and offers higher selectivity and different pharmacokinetics compared to the older PDE5-inhibitors, which were launched about twenty years ago. Spedra is available in Sweden, Norway and Denmark and has gained much interest from urologists, sexologists and ED sufferers since then.

Spedra (avanafil), Tablet, Rx, EF

ATC code

Indication area
Treatment of erectile dysfunction in adult men. In order for Spedra to be effective, sexual stimulation is required.

Pharmaprim (Product website)

Last SPC review

A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered. 

Please carefully study the information contained in the leaflet or, as applicable, on the outer packaging.

Please refer to www.fass.se for more information regarding price, more specific warnings etc.

Please note that the information you will find in this section is for healthcare professionals

Please confirm that you are a healthcare professional